Search
for

    Glossary Enzalutamide

    blocks male hormones to treat prostate cancer

    Enzalutamide, also known by the brand name Xtandi, is a medication used to treat prostate cancer. It works by blocking the action of androgens (male hormones) that can promote the growth of cancer cells. This drug is particularly used in cases where the cancer has spread to other parts of the body and is resistant to other treatments.

    Research 10 of 132

    1. The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells Nature Communications · 2021 · 50 citations
    2. TMPRSS2, required for SARS-CoV-2 entry, is downregulated in lung cells by enzalutamide, a prostate cancer therapeutic Research Square (Research Square) · 2020 · 2 citations
    3. Enzalutamide, a prostate cancer therapeutic, downregulates TMPRSS2 in lung and reduces cellular entry of SARS-CoV-2 Research Square (Research Square) · 2021 · 1 citations
    4. Enzalutamide/finasteride/goserelin/zoledronic-acid Reactions Weekly · 2024
    5. Androgenic Effects on Ventricular Repolarization Circulation · 2019 · 64 citations
    6. Redefining hormone resistance in prostate cancer Therapeutic Advances in Medical Oncology · 2009 · 38 citations
    7. Recent discoveries and developments of androgen receptor based therapy for prostate cancer MedChemComm · 2015 · 17 citations
    8. Androgen Receptor in Human Health: A Potential Therapeutic Target Current Drug Targets · 2012 · 12 citations
    9. Global Trends in Research of Androgen Receptor Associated With Breast Cancer From 2011 to 2020: A Scientometric Analysis Frontiers in Endocrinology · 2022 · 5 citations
    10. Cortexolone 17α-Propionate (Clascoterone) is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro PubMed · 2019 · 4 citations
    All research results →

    Learn

    — no results

    Try a deeper search in learn →

    Community

    — no results

    Try a deeper search in community →